Tdspharm Co., Ltd. (KOSDAQ:464280)

Tdspharm Statistics

Total Valuation

Tdspharm has a market cap or net worth of KRW 61.71 billion. The enterprise value is 39.87 billion.

Market Cap	61.71B
Enterprise Value	39.87B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Tdspharm has 5.53 million shares outstanding. The number of shares has increased by 14.79% in one year.

Current Share Class	5.53M
Shares Outstanding	5.53M
Shares Change (YoY)	+14.79%
Shares Change (QoQ)	-0.05%
Owned by Insiders (%)	91.89%
Owned by Institutions (%)	4.27%
Float	422,556

Valuation Ratios

The trailing PE ratio is 16.65.

PE Ratio	16.65
Forward PE	n/a
PS Ratio	2.43
PB Ratio	1.59
P/TBV Ratio	1.59
P/FCF Ratio	30.76
P/OCF Ratio	22.63
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.92, with an EV/FCF ratio of 19.87.

EV / Earnings	12.17
EV / Sales	1.57
EV / EBITDA	10.92
EV / EBIT	13.37
EV / FCF	19.87

Financial Position

The company has a current ratio of 3.79, with a Debt / Equity ratio of 0.17.

Current Ratio	3.79
Quick Ratio	3.49
Debt / Equity	0.17
Debt / EBITDA	1.81
Debt / FCF	3.29
Interest Coverage	11.73

Financial Efficiency

Return on equity (ROE) is 10.46% and return on invested capital (ROIC) is 4.88%.

Return on Equity (ROE)	10.46%
Return on Assets (ROA)	4.47%
Return on Invested Capital (ROIC)	4.88%
Return on Capital Employed (ROCE)	7.64%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.61
Inventory Turnover	6.98

Taxes

In the past 12 months, Tdspharm has paid 312.17 million in taxes.

Income Tax	312.17M
Effective Tax Rate	8.70%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	11,512.00
200-Day Moving Average	13,747.40
Relative Strength Index (RSI)	49.42
Average Volume (20 Days)	30,135

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Tdspharm had revenue of KRW 25.43 billion and earned 3.28 billion in profits. Earnings per share was 670.09.

Revenue	25.43B
Gross Profit	7.00B
Operating Income	2.98B
Pretax Income	3.59B
Net Income	3.28B
EBITDA	3.65B
EBIT	2.98B
Earnings Per Share (EPS)	670.09

Balance Sheet

The company has 28.45 billion in cash and 6.60 billion in debt, giving a net cash position of 21.85 billion or 3,951.08 per share.

Cash & Cash Equivalents	28.45B
Total Debt	6.60B
Net Cash	21.85B
Net Cash Per Share	3,951.08
Equity (Book Value)	38.87B
Book Value Per Share	7,350.02
Working Capital	26.61B

Cash Flow

In the last 12 months, operating cash flow was 2.73 billion and capital expenditures -720.47 million, giving a free cash flow of 2.01 billion.

Operating Cash Flow	2.73B
Capital Expenditures	-720.47M
Free Cash Flow	2.01B
FCF Per Share	362.78

Margins

Gross margin is 27.53%, with operating and profit margins of 11.72% and 12.88%.

Gross Margin	27.53%
Operating Margin	11.72%
Pretax Margin	14.10%
Profit Margin	12.88%
EBITDA Margin	14.35%
EBIT Margin	11.72%
FCF Margin	7.89%

Dividends & Yields

Tdspharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.79%
Shareholder Yield	-14.79%
Earnings Yield	5.31%
FCF Yield	3.25%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Tdspharm has an Altman Z-Score of 8.32 and a Piotroski F-Score of 5.

Altman Z-Score	8.32
Piotroski F-Score	5